News | August 27, 2024
Mangalam Drugs & Organics awarded US$ 274,800 grant by MMV
The grant is designated for the research and development of Pyronaridine
The grant is designated for the research and development of Pyronaridine
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Our centers are performing as expected or even better
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Revolutionary technology will further boost OneSource’s scientific services offerings
Subscribe To Our Newsletter & Stay Updated
